StockData
Faeth Therapeutics, Inc. logo

Faeth Therapeutics, Inc. (FTH) stock

FTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$8.72−0.32 (-3.54%)

Close on Nov 18, 2026Market cap $225.33MP/E –Yield –

Faeth Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Faeth Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$33.86M. For fiscal 2025 it was -$20.47M. The highest annual figure on record is -$18.91M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$20.47M–
FY2024Dec 31, 2024-$24.82M–
FY2023Dec 31, 2023-$32.20M–
FY2022Dec 31, 2022-$39.35M–
FY2021Dec 31, 2021-$32.29M–
FY2020Dec 31, 2020-$18.91M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.67M–
Q1 FY2026Mar 31, 2026-$10.74M–
Q4 FY2025Dec 31, 2025-$3.86M–
Q3 FY2025Sep 30, 2025-$3.59M–
Q2 FY2025Jun 30, 2025-$5.93M–
Q1 FY2025Mar 31, 2025-$7.09M–
Q4 FY2024Dec 31, 2024-$5.79M–
Q3 FY2024Sep 30, 2024-$5.47M–
Q2 FY2024Jun 30, 2024-$5.90M–
Q1 FY2024Mar 31, 2024-$7.65M–
Q4 FY2023Dec 31, 2023-$6.16M–
Q3 FY2023Sep 30, 2023-$4.66M–
Q2 FY2023Jun 30, 2023-$9.49M–
Q1 FY2023Mar 31, 2023-$11.89M–
Q4 FY2022Dec 31, 2022-$9.57M–
Q3 FY2022Sep 30, 2022-$7.05M–
Q2 FY2022Jun 30, 2022-$11.95M–
Q1 FY2022Mar 31, 2022-$10.77M–
Q4 FY2021Dec 31, 2021-$8.40M–
Q3 FY2021Sep 30, 2021-$5.97M–
Q2 FY2021Jun 30, 2021-$6.66M–
Q1 FY2021Mar 31, 2021-$11.25M–
Q4 FY2020Dec 31, 2020-$3.00M–
Q3 FY2020Sep 30, 2020-$6.63M–
Q2 FY2020Jun 30, 2020-$2.77M–
Q1 FY2020Mar 31, 2020-$6.51M–

More Faeth Therapeutics figures

See a number that looks wrong?